Tonix Q3 net loss widens to $29M on higher R&D spend; cash at $140M

Tonix Pharmaceuticals Holding Corp.

2022-Q3 EPS reported -$3.06

Net loss $29.0M ($0.69/sh) vs $18.5M ($1.60/sh) in Q3 2021; share count rose to 41.9M from 11.6M.
Cash and equivalents $140M at Sept 30, 2022, down from $178.7M at Dec 31, 2021.
R&D expenses $22.2M in Q3 2022 vs $13.1M in Q3 2021, driven by clinical and manufacturing costs.
Raised $15.0M in Oct 2022 via private placement of Series A/B convertible redeemable preferred stock.
Interim data from Phase 3 fibromyalgia and Phase 2 Long COVID TNX-102 SL studies expected in Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-22-011124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.